stockrow
Friday 6 November 2026
Export ONC’s income statement to Excel — free account
BeOne Medicines Ltd. - Sponsored ADR
BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.
- Revenue
- +33.8%
- EPS
- +143.7%
- Free cash flow
- +33.6%
- Total debt
- +491.3%
Quarter to September 2026, against a year earlier
406.26
19.01
+4.91%
Follow ONC
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
116.40 | 63.86 | 48.30 | 62.02 |
P/S ratio |
6.20 | 5.74 | 5.19 | 6.18 | |
P/FCF ratio |
35.95 | 30.10 | 24.27 | 28.57 | |
P/Operating CF |
79.39 | 163.66 | 68.70 | 80.26 | |
P/B ratio |
7.60 | 6.92 | 6.15 | 7.02 | |
Price to Tangible BV |
7.71 | 7.01 | 6.22 | 7.06 | |
EV/Sales |
5.59 | 5.13 | 4.55 | 5.48 | |
EV/EBITDA |
50.74 | 35.23 | 25.89 | 26.67 | |
EV/Operating CF |
26.50 | 22.92 | 18.81 | 22.77 | |
EV/FCF |
32.41 | 26.91 | 21.30 | 25.33 | |
Quick Ratio |
2.96 | 3.16 | 2.90 | 3.08 | |
Current Ratio |
3.41 | 3.64 | 3.41 | 3.55 | |
Net Debt/EBITDA |
(16.22) | (13.16) | (11.53) | (10.33) | |
Debt/Assets |
11.75% | 11.25% | 9.61% | 8.36% | |
Debt/Equity |
0.22 | 0.20 | 0.17 | 0.14 | |
Asset Turnover |
0.76 | 0.80 | 0.79 | 0.75 | |
Operating CF/Net income |
6.28 | 0.89 | 1.95 | 1.32 | |
Capex/Depreciation |
(1.04) | (0.99) | (0.68) | (0.58) | |
Interest Coverage |
4.28 | 7.60 | 8.18 | — | |
Research and Development Expense of Revenue |
41.08% | 35.76% | 35.91% | 34.97% | |
Selling, General and Administrative Expense of Revenue |
37.06% | 36.68% | 34.79% | 31.40% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.00 | |
Share Based Compensation of Revenue |
8.26% | 8.15% | 8.06% | 7.01% | |
Graham Net Nets |
0.07 | 0.09 | 0.10 | 0.09 | |
Graham Number |
48.46 | 67.00 | 78.46 | 0.00 | |
Earnings Yield |
0.86% | 1.57% | 2.07% | 1.61% | |
Free Cash Flow Yield |
2.78% | 3.32% | 4.12% | 3.50% | |
Revenue per Share |
13.74 | 13.64 | 15.28 | 0.00 | |
Operating CF per Share |
3.83 | 1.81 | 4.15 | 0.00 | |
Capex per Share |
(0.34) | (0.37) | (0.25) | 0.00 | |
Free Cash Flow per Share |
3.48 | 1.45 | 3.90 | 0.00 | |
Cash per Share |
41.70 | 43.18 | 45.69 | 0.00 | |
Shareholders Equity per Share |
39.99 | 42.90 | 46.37 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
39.99 | 42.90 | 46.37 | 0.00 | |
Free Cash Flow |
379.83 | 160.55 | 435.34 | 473.53 | |
Working Capital |
4,404.76 | 4,789.77 | 5,096.62 | 5,697.32 | |
Capital Expenditures |
(37.52) | (40.79) | (27.48) | (35.17) | |
Net Current Asset Value |
2,406.21 | 2,808.10 | 3,214.19 | 3,875.71 | |
EV/EBIT |
66.82 | 42.94 | 30.23 | 30.72 | |
Capex to Sales |
0.03 | 0.03 | 0.02 | 0.02 | |
Price to Operating Income |
74.10 | 48.04 | 34.44 | 34.64 | |
| Other line items | |||||
Average Receivables |
770.68 | 827.63 | 913.48 | 977.91 | |
Average Payables |
442.02 | 394.02 | 415.54 | 440.28 | |
Average Inventory |
551.61 | 588.13 | 617.74 | 669.80 | |
Average Assets |
7,054.74 | 7,197.57 | 7,737.00 | 8,754.26 | |
Average Common Equity |
3,846.71 | 4,129.98 | 4,472.24 | 4,974.86 |
Columns are period end dates · fundamentals updated 5 Nov 2026